Clonidine Pediatric Dose — Sedation & Withdrawal
Clonidine is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, producing sedation, analgesia, and anxiolysis. In pediatric critical care, it is used as an adjunctive agent alongside opioids and/or benzodiazepines to facilitate sedation, minimize opioid requirements, and manage iatrogenic withdrawal syndromes.
Pediatric Dosing
The recommended oral dose of clonidine is 1.5–5 mcg/kg/dose administered every 8 hours by mouth, used in addition to an opioid and/or benzodiazepine. Consult institutional protocol regarding weight-based maximum single dose and titration strategy.
- Route: Oral (PO)
- Frequency: Every 8 hours
- Indication: Adjunctive sedation or opioid/benzodiazepine-sparing in the PICU setting
Worked example: For a 20 kg child, the dose range is 20 × 1.5 mcg/kg = 30 mcg to 20 × 5 mcg/kg = 100 mcg per dose, administered every 8 hours alongside concurrent opioid and/or benzodiazepine therapy.
Indications and Clinical Context
Clonidine is employed as an adjunctive sedative in pediatric intensive care when opioids and/or benzodiazepines alone provide insufficient sedation or when a dose-sparing strategy is desired to reduce cumulative opioid exposure. It is particularly useful in managing iatrogenic opioid or benzodiazepine withdrawal following prolonged infusions, as its alpha-2 agonism attenuates sympathetic hyperactivity characteristic of withdrawal states.
Use of clonidine in this context aligns with multimodal analgosedation frameworks advocated in current PICU practice guidelines, which emphasize minimizing benzodiazepine and opioid burden while maintaining adequate patient comfort. It is classified within the sedative/analgesic adjunct category and is not considered a first-line standalone sedative for critically ill children.
Administration and Monitoring
Clonidine is administered orally at the doses described; the tablet may be crushed and administered via nasogastric or orogastric tube in patients unable to swallow. It should always be given as an adjunct—not as monotherapy—alongside a concurrent opioid and/or benzodiazepine regimen as stated in the source dosing description.
- Hemodynamic monitoring: Monitor blood pressure and heart rate closely; bradycardia and hypotension are the principal adverse effects.
- Rebound hypertension: Avoid abrupt discontinuation; taper clonidine gradually to prevent rebound sympathetic activation.
- Sedation level: Assess using a validated pediatric sedation scale (e.g., COMFORT-B or SBS) at regular intervals.
- Renal impairment: Clonidine is renally cleared; consult institutional protocol for dose adjustments in patients with significant renal dysfunction.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.